251 related articles for article (PubMed ID: 23291208)
41. Substance use disorders in individuals with body dysmorphic disorder.
Grant JE; Menard W; Pagano ME; Fay C; Phillips KA
J Clin Psychiatry; 2005 Mar; 66(3):309-16; quiz 404-5. PubMed ID: 15766296
[TBL] [Abstract][Full Text] [Related]
42. Dual Diagnosis and Suicide Probability in Poly-Drug Users.
Youssef IM; Fahmy MT; Haggag WL; Mohamed KA; Baalash AA
J Coll Physicians Surg Pak; 2016 Feb; 26(2):130-3. PubMed ID: 26876401
[TBL] [Abstract][Full Text] [Related]
43. [Dual diagnosis in psychoactive substance abusing or dependent persons].
Błachut M; Badura-Brzoza K; Jarzab M; Gorczyca P; Hese RT
Psychiatr Pol; 2013; 47(2):335-52. PubMed ID: 23888766
[TBL] [Abstract][Full Text] [Related]
44. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses.
Caton CL; Drake RE; Hasin DS; Dominguez B; Shrout PE; Samet S; Schanzer B
Arch Gen Psychiatry; 2005 Feb; 62(2):137-45. PubMed ID: 15699290
[TBL] [Abstract][Full Text] [Related]
45. Assessment of decisional capacity: Prevalence of medical illness and psychiatric comorbidities.
Boettger S; Bergman M; Jenewein J; Boettger S
Palliat Support Care; 2015 Oct; 13(5):1275-81. PubMed ID: 25355466
[TBL] [Abstract][Full Text] [Related]
46. Psychiatric symptoms and disorders in HIV infected mine workers in South Africa. A retrospective descriptive study of acute first admissions.
Säll L; Salamon E; Allgulander C; Owe-Larsson B
Afr J Psychiatry (Johannesbg); 2009 Aug; 12(3):206-12. PubMed ID: 19750249
[TBL] [Abstract][Full Text] [Related]
47. Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV.
Torrens M; Serrano D; Astals M; Pérez-Domínguez G; Martín-Santos R
Am J Psychiatry; 2004 Jul; 161(7):1231-7. PubMed ID: 15229056
[TBL] [Abstract][Full Text] [Related]
48. Comorbidity of severe psychotic disorders with measures of substance use.
Hartz SM; Pato CN; Medeiros H; Cavazos-Rehg P; Sobell JL; Knowles JA; Bierut LJ; Pato MT;
JAMA Psychiatry; 2014 Mar; 71(3):248-54. PubMed ID: 24382686
[TBL] [Abstract][Full Text] [Related]
49. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment.
Shoptaw S; Peck J; Reback CJ; Rotheram-Fuller E
J Psychoactive Drugs; 2003 May; 35 Suppl 1():161-8. PubMed ID: 12825759
[TBL] [Abstract][Full Text] [Related]
50. Lifetime history of substance misuse in first-episode psychosis: prevalence and its influence on psychopathology and onset of psychotic symptoms.
Kamali M; McTigue O; Whitty P; Gervin M; Clarke M; Browne S; Larkin C; O'Callaghan E
Early Interv Psychiatry; 2009 Aug; 3(3):198-203. PubMed ID: 22640383
[TBL] [Abstract][Full Text] [Related]
51. [Comorbidity in 207 cannabis users in a specific outpatient setting].
Guillem E; Arbabzadeh-Bouchez S; Vorspan F; Bellivier F
Encephale; 2015 Jun; 41 Suppl 1():S7-12. PubMed ID: 25123065
[TBL] [Abstract][Full Text] [Related]
52. Dual diagnosis in the suburbs: prevalence, need, and in-patient service use.
Wright S; Gournay K; Glorney E; Thornicroft G
Soc Psychiatry Psychiatr Epidemiol; 2000 Jul; 35(7):297-304. PubMed ID: 11016524
[TBL] [Abstract][Full Text] [Related]
53. Psychiatric comorbidity in binge-eating disorder as a function of smoking history.
White MA; Grilo CM
J Clin Psychiatry; 2006 Apr; 67(4):594-9. PubMed ID: 16669724
[TBL] [Abstract][Full Text] [Related]
54. Demographic and clinical correlates of substance use disorders in first episode psychosis.
Brunette MF; Mueser KT; Babbin S; Meyer-Kalos P; Rosenheck R; Correll CU; Cather C; Robinson DG; Schooler NR; Penn DL; Addington J; Estroff SE; Gottlieb J; Glynn SM; Marcy P; Robinson J; Kane JM
Schizophr Res; 2018 Apr; 194():4-12. PubMed ID: 28697856
[TBL] [Abstract][Full Text] [Related]
55. Substance abuse in psychotic disorders: associations with affective syndromes. DSM-IV Field Trial Work Group.
Strakowski SM; Tohen M; Flaum M; Amador X
Schizophr Res; 1994 Dec; 14(1):73-81. PubMed ID: 7893624
[TBL] [Abstract][Full Text] [Related]
56. Behavioral interventions for dual-diagnosis patients.
Goldsmith RJ; Garlapati V
Psychiatr Clin North Am; 2004 Dec; 27(4):709-25. PubMed ID: 15550289
[TBL] [Abstract][Full Text] [Related]
57. Mental capacity, diagnosis and insight in psychiatric in-patients: a cross-sectional study.
Owen GS; David AS; Richardson G; Szmukler G; Hayward P; Hotopf M
Psychol Med; 2009 Aug; 39(8):1389-98. PubMed ID: 18940026
[TBL] [Abstract][Full Text] [Related]
58. [Motivational interviewing for cannabis users with psychotic disorders].
Bonsack C; Montagrin Y; Favrod J; Gibellini S; Conus P
Encephale; 2007 Oct; 33(5):819-26. PubMed ID: 18357854
[TBL] [Abstract][Full Text] [Related]
59. Predictors of psychosis remission in psychotic disorders that co-occur with substance use.
Caton CL; Hasin DS; Shrout PE; Drake RE; Dominguez B; Samet S; Schanzer B
Schizophr Bull; 2006 Oct; 32(4):618-25. PubMed ID: 16873441
[TBL] [Abstract][Full Text] [Related]
60. Psychiatric and Substance Use Comorbidity in Treatment-Seeking Injection Opioid Users Referred From Syringe Exchange.
Kidorf M; Solazzo S; Yan H; Brooner RK
J Dual Diagn; 2018; 14(4):193-200. PubMed ID: 30332349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
